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The metabolism and toxicity ofthe ubiquitous plasticizer, bis-(2-ethylhexyl) phthalate (DEHP), and its
principal metabolite, mono-(2-ethylhexyl) phthalate (MEHP), have been extensively investigated. In an
attempt to understand their disposition in man, we studied the in vitro serum protein-binding character-
istics of these compounds, using ultracentrifugation and agarose gel electrophoresis. The association of
DEHPandlipoproteins wasshowntobehighlydependentupon, andproportional to, thelipidconcentration
ofthe serum. It appears that more than halfofthe serum DEHP is bound to proteins with density greater
than 1.21 g/mL when the concentration ofcholesterol isbelow300 mg/dL orthecholesterol andtriglyceride
total concentration is less than 600 mg/dL. As the cholesterol and triglyceride concentrations increase,
the percent DEHP bound toVLDL, IDL, and LDLincreases. MEHP is boundprincipally tononlipoprotein
constituents in the serum, and this binding distribution is unaffected by lipid concentration. The percent
binding ofDEHP and MEHP to individual proteins was alsofoundtobeunaffected bytheirconcentrations
in serum. These data indicate that the protein-binding characteristics of these compounds, in vitro, is
somewhat more complex than previously reported.
Introduction
The commonly used plastic polyvinylchloride (PVC),
which is naturally rigid, is made flexible by the addition
of plasticizing agents during its formulation process.
The most common of these agents is bis-(2-ethylhexyl)
phthalate (DEHP), which may comprise 20 to 40% of
the final product. Ofparticular concern is its use in the
manufacture ofblood bank bags, other medical devices,
and in more accessible items such as food wrappers,
childrens' toys, and synthetic leathers. When in contact
with blood and blood products, leaching ofDEHP takes
place, resulting in the introduction of substantial
amounts into units ofblood after several hours of stor-
age (1-3) and into hemodialysis patients after dialysis
(4,5). For example, Contreras and co-workers report
that the accumulation of DEHP in the plasma of PVC-
stored whole blood was 3.6 ,ug/mL/day if the antico-
agulant was acid-citrate-dextrose, and 2.7 ,ug/mL/day
in the presence of citrate-phosphate-dextrose (6).
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The biological effects of DEHP have been studied in
numerous tissue and organ systems, as well as in a
variety ofspecies, the results ofwhich have been thor-
oughly reviewed (7,8). The acute toxicity is very low,
but chronic exposure trials in rats demonstrated pro-
gressive enlargement of the liver, induction of the cy-
tochrome P-450 enzyme system, and proliferation ofhe-
patic peroxisomes. Most importantly, chronic exposure
for 2 years at very high doses produced hepatocarci-
noma in mice and rats (9).
Clearly, the ubiquitous nature of this compound
makes it certain that everyone is constantly exposed.
An important question is, What is its concentration in
man at any one time and where is it located? In an
attempttounderstanditsdispositioninman, westudied
the serum protein-binding characteristics ofDEHP and
its principal metabolite, mono-(2-ethyhexyl) phthalate
(MEHP).
Previous studies indicated that DEHP is predomi-
nantly bound to lipoprotein in the blood (2,3,10-15),
whereasMEHPhasanaffinityforalbumin(15-17). Jae-
ger and Rubin (2) have shown that in human plasma
fractionated from 1 pint of whole blood stored for 14
days, 29% ofthe DEHP is associated withproteins with
density greater than 1.21 g/mL and 71% with the lipo-GRIFFITHS ET AL.
protein fraction (d < 1.21 g/mL). Albro and Corbett
indicate that more than 80% of DEHP in plasma is as-
sociatedwiththelipoproteins (15). Thisstudy, however,
used acombination ofprecipitationtechniques andglass
bead chromatography to separate the protein fractions.
Dissociation of the plasticizer from the protein and re-
distributionarelikelycomplications ofthesetechniques.
Pike and co-workers (18) reported that DEHP dis-
places basic drugs from serum binding sites, ostensibly
on orosomucoid. Acidic drugs were unaffected. The re-
ported effect was minor, however. For example, the
greatest effect was on the binding of quinidine at 10
pimole/L, which was reduced from 74% to 67% as the
concentration of DEHP increased from 0 to 0.5
mmole/L. Further increases in DEHP concentration up
to 2.5 mmole/L produced no further changes in the
bound fraction of quinidine.
In related observations, Sasakawa and Mitomi re-
ported that the rate of extraction of DEHP by blood,
from PVC bags, was directly related to the lipid con-
centration ofthe blood (10). Pollack and co-workers re-
ported that the rate (but not the amount) ofextraction
ofDEHP from plasma varies inversely with the sum of
the cholesterol and triglyceride concentrations (19).
We examined the in vitro serum protein binding of
DEHP and MEHP using a combination of ultracentri-
fugation and agarose gel electrophoresis. We have also
studied the effect of serum lipid concentration on the
protein distribution of DEHP and MEHP. Our inves-
tigation of the binding of DEHP is relevant when con-
sidering its introduction via blood transfusion or dialy-
sis. Serum protein binding ofMEHP is pertinent when
ingestionistheprincipalroute ofintroduction ofDEHP,
given that DEHP is extensively hydrolysed in the gut
(20).
Materials and Methods
DEHP and MEHP
Unlabeled DEHP was obtained from Aldrich Chem-
ical Company (Milwaukee, WI). 14C-DEHP was ob-
tained from Dupont/NEN Products (Boston, MA) asthe
carbonyl-14C form. Purity of each was confirmed by
thin-layer chromatography. 14C-Labeled and unlabeled
MEHP were synthesized and purified as previously de-
scribed (21,22). The identity ofthe synthesized product
was confirmed by infrared spectrophotometry. Thin-
layer chromatography (TLC) and high-pressure liquid
chromatography (HPLC) were used to demonstrate
that the product was free ofphthalic acid, phthalic an-
hydride, and DEHP. The specific activity of14C-MEHP
was 1.1 mCi/mmole.
Specimen Preparation for
Ultracentrifugation and Electrophoresis
Fasting serumspecimens fromhospitalin-patients on
which cholesterol and triglyceride assays had been or-
dered and performed were pooled to achieve samples
with various concentrations of cholesterol and triglyc-
eride. Cholesterol analysis was performed using a cho-
lesterol ester hydrolase/cholesterol oxidase method on
the American Monitor KDA (American Monitor, Indi-
anapolis, IN). Triglyceride was determined with an en-
zymatic method using Sigma reagents (Sigma Diagnos-
tics, St. Louis, MO).
The original ampule of14C-DEHP (0.49 mCi, specific
activity = 32.6 mCi/mmole) was diluted to 10 mL with
acetone (stock solution), and a working solution was
prepared as needed (100 ,LL of stock into 10 mL of
acetone). The final concentration ofDEHP in the work-
ingsolutionwas 5.9ng/,uL. Then, 75pL1 (0.4jigDEHP)
of the working solution was added to 5-mL serum ali-
quots and incubated for 16 hr at 37°C under an atmos-
phere of5% CO2 to maintain constant pH. To study the
effect of DEHP concentration, labeled and unlabeled
DEHP were added to the incubation mixture to yield
the following concentrations: 14.8 ng/mL, 0.99 ,ug/mL,
24.5 ,ug/mL, 49.0 ,ug/mL, 0.49mg/mL, and0.98mg/mL.
Atthe end oftheincubationperiod, the specimens were
subjected to density gradient ultracentrifugation and
agarose gel electrophoresis. Specimen stability at re-
frigerator temperatures was tested by labeling serum
samples asdescribedabove, andthenfractionatingafter
0, 24, and 48 hr of storage at 4 to 6°C.
Similarly, 25-[uL aliquots ofpurified 14C-MEHP were
added to 5 mL serum aliquots and were incubated as
described above. The concentration study was accom-
plished by spiking sera with labeled and unlabeled
MEHP to achieve specimens with the following concen-
trations: 25, 30, 75, 225, 525, and 1025 ,ug/mL.
Ultracentrifugation and Electrophoresis
Density gradient ultracentrifugation was performed
following the protocol ofTerpstra et al. (23). After cen-
trifugation, the fractions were isolated and counted by
liquid scintillation to determine the position of the ra-
dioactively labeled moieties. The following densities
wereusedtodefinethevariouscentrifugalzones:VLDL
= d < 1.00 g/mL; IDL = 1.006-1.019 g/mL; LDL =
1.019-1.063 g/mL; HDL2 = 1.063-1.125 g/mL; HDL3,
= 1.125-1.21 g/mL; plasma proteins > 1.21 g/mL. As
a control for the ultracentrifugation procedure, speci-
mens spiked with 3H-cholesterol and 14C-phenytoin
were incubated and fractionated. Distribution was then
comparedtothepreviouslyreporteddataforthesecom-
pounds.
Agarose gel electrophoresis was accomplished using
established techniques, with the Corning Electropho-
retic system (Corning Medical and Scientific, Medfield,
MA). Controls, sera incubated with 14C-DEHP as
above, as well as unincubated (cold) sera, were all run
in duplicate on each membrane. After electrophoresis,
the control and cold sera zones were stained with Fat
Red 7B forvisualization oflipoproteins and with Amido
Black 10B for the staining oftotal serum proteins. The
channels containingthe labeled specimens were cut into
5-mm strips. They were placed in liquid scintillation
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Table 1. Protein binding of DEHP demonstrated by density gradient ultracentrifugation.
Cholestrol, Triglyceride, % VLDL % Serum
Spec ID mg/dL mg/dL IDL + LDL % HDL2 % HDL3 protein
PD#5 156 105 18.5 6.0 3.3 72.0
PE#4 176 116 21.2 5.1 4.5 69.3
PC#4 180 125 25.2 6.6 4.0 64.2
PF#5 198 106 18.1 7.1 3.5 71.3
A#1 213 88 25.3 5.3 5.4 64.0
PJ#4-3 228 149 25.9 7.2 3.3 63.4
PB#2 275 220 27.1 4.6 3.0 65.2
PA#6 295 273 32.2 6.7 3.9 57.2
#2 310 295 51.7 2.2 2.9 38.5
#1 330 305 68.1 4.0 3.0 25.0
PG#6-3 342 508 46.7 4.6 3.5 45.1
IST#1 376 553 68.3 2.7 2.8 23.0
cocktail and counted for 10 min or 10,000 counts. Elec-
trophoreticmigrationforagivenlabeledcomponent was
then compared to the stainingpattern ofthe cold serum
specimen to which it corresponded.
Results
The control experiment for the ultracentrifugation
procedure showed 3H-cholesterol binding predomi-
nantly to the VLDL, IDL, and LDL fractions (84.4%),
with some binding to HDL (13.6%), and the remainder
inthe nonlipoproteinfraction (2.0%). The 14C-phenytoin
was found principally in the plasma protein fraction
(96.0%), withtheremaining4.0% distributed amongthe
lipoprotein fractions.
Table 1 showsthe datafor 13human serumspecimens
that were incubated overnight with 14C-DEHP then
subjected to density gradient ultracentrifugation. It ap-
pears from these data that more than halfofthe serum
DEHP binds to proteins with d > 1.21 g/mL when the
concentration of cholesterol is below 300 mg/dL. Our
resultsshowthatascholesterol concentrationincreases,
the percent DEHP bound to the VLDL, IDL, and LDL
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FIGURE 2. Total concentration ofcholesterol plustriglyceride versus
percent DEHP bound to VLDL, IDL plus LDL.
increasesconcomitantly (r = 0.88) (Fig. 1). Weobtained
similar results when comparing triglyceride concentra-
tion and the binding of DEHP to these fractions (r =
0.82). It should be noted, however, that triglyceride
and cholesterol are not independent variables for our
sample set. Using the total cholesterol and triglyceride
concentration versuspercent DEHPbound tothesecon-
stituents doesnotsignificantly alterthecorrelationcoef-
ficient (r = 0.86) (Fig. 2).
Our studies also showed that when serum specimens
were left at4 to 6°C for t = 24 and t = 48hr, the protein
binding pattern of DEHP did not change from that at
t = 0 hr, indicating stability ofthe DEHP-protein com-
plex at these temperatures.
Fourofthethirteen specimens were also electrophor-
esed in agarose gel (Fig. 3). Table 2 lists the counts per
minute recovered from the 5-mm strips cut from the
radioactive channel of the electrophoresis membrane.
The numbers are the average ofduplicate experiments.
Also listed is the percentage of total recovered counts
corresponding to each strip. The location ofmajor pro-
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binding of DEHP to nonlipoprotein constituents that
migrate in the a2 region. A major portion of nonlipo-
protein bound DEHP appears to be bound to prealbu-
min.
Ultracentrifugation data for serum incubated with
14C-MEHP (Table 3) shows preferential binding to
plasma proteins (d < 1.21 g/mL), regardless ofthe cho-
lesterol and triglyceride concentrations. Average
plasma protein binding for all 14C-MEHP specimens =
73.9 ± 2.7% (n = 8). Of the remaining 26.1% of 14C-
MEHP that is bound to lipoproteins, 15.3% is bound to
HDL3.
Increasing the concentration of DEHP or MEHP in
the serum samples did not affect the protein-binding
pattern of these compounds. For a specimen with cho-
lesterol of 376 mg/dL and triglyceride of 553 mg/dL,
the average percent DEHP bound to VLDL, IDL, and
LDL = 68.3 + 5.0% (n = 6)asthe DEHP concentration
was increased from 14.8 ng/mL to 0.98 mg/mL. Simi-
larly, for a specimen with cholesterol of211 mg/dL and
triglyceride of 134 mg/dL, MEHP showed an average
plasma protein binding of 84.5 ± 2.6% (n = 6) as the
MEHP concentration was increased from25 to 1025 p,g/
mL.
FIGURE 3. Agarose gel electrophoresis of sample serum before in-
cubation with "4DEHP and control serum (indicated by arrows),
stained for lipoproteins (above) and total serum proteins (below).
Ruled lines indicatefractionstakenforliquid scintillation counting.
tein and lipoprotein factors with respect to the 5-mm
strips is indicated in the table.
The results from these experiments parallel the ul-
tracentrifugation data showing the greater amount of
radioactivity in the P, a2, and prealbumin regions. The
actual percent radioactivity in the a2 (pre-beta) region
(mean = 38%, n = 8) indicates somewhat more binding
than is evidenced by the centrifugation data for VLDL,
IDL, and LDL, suggesting that there may be some
Discussion
The results ofthis studyindicatethatthe distribution
ofDEHP amonghuman serumproteinsinvitro is some-
what more complex than previously reported. The ob-
servationthat DEHPpreferentially associateswith pro-
teins ofd > 1.21 g/mL when cholesterol concentrations
were less than 300 mg/dL contrasts with the previous
reports (vida supra) suggesting that DEHP, in blood,
isprimarilyboundtolipoproteins. These earlierstudies,
however, did not indicate the total cholesterol and tri-
glyceride content of the tested specimens. The results
of our ultracentrifugation studies indicate that the frac-
tion of DEHP that binds to VLDL, IDL, and LDL is
Table 2. The distribution of 14C-DEHP on agarose electrophoresis with respect to the major protein and lipoprotein fractions.
Lipoprotein
regions Zone
6.0
7.0
13 8.0
i 9.0
1 10.00
11.00
a 12.00
a 13.00
14.00
15.00
16.00
17.00
18.00
19.00
20.00
21.00
aCPM, counts per minute.
b%, percent of total counts.
PA, CPMa
0.00
0.00
132.00
891.50
2838.50
2712.00
434.00
488.00
1976.50
1609.00
719.00
96.50
23.50
13.00
11.00
7.50
PA, %b
0.00
0.00
1.10
7.46
23.74
22.69
3.63
4.08
16.00
13.46
6.01
0.79
0.20
0.11
0.09
0.06
PB, CPM
0.00
0.00
138.00
266.50
1364.50
1142.00
192.00
536.50
2869.00
268.50
50.00
2.00
0.00
0.00
0.00
0.00
PB, %
0.00
0.00
2.02
3.90
19.98
16.72
2.81
7.86
42.01
3.93
0.73
0.03
0.00
0.00
0.00
0.00
PC CPM
0.00
0.00
585.00
643.00
3316.00
1143.00
678.00
1445.00
4580.00
282.00
16.50
10.50
9.50
4.00
0.00
0.00
Serum
protein
regions
'Y
a2
a2
al
Albumin
Prealbumin
Prealbumin
PC, %
0.00
0.00
4.60
5.06
26.08
8.99
5.33
11.37
36.03
2.22
0.13
0.08
0.07
0.03
0.00
0.00
PE, CPM
0.00
0.00
329.00
366.00
1506.00
624.00
261.00
491.50
1715.50
731.50
187.50
21.50
2.00
0.00
0.00
0.00
PE, %
0.00
0.00
5.28
5.87
24.15
10.01
4.19
7.88
27.51
11.73
3.01
0.34
0.03
0.00
0.00
0.00
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Table 3. Protein binding of MEHP demonstrated by density gradient ultracentrifugation.
Cholestrol, Triglyceride, % VLDL, % Serum
Spec ID mg/dL mg/dL IDL + LDL %HDL2 % HDL3 protein
PD#5 156 105 3.1 6.0 14.7 76.1
PC#3 180 125 6.7 3.7 13.8 75.9
PF#3 198 106 4.2 4.9 16.0 74.8
PB#2 275 220 6.1 5.6 15.1 73.0
PA#1 295 273 7.1 6.6 15.7 70.5
PI#3-3 333 516 4.0 3.5 14.7 77.7
PG#1-3 342 508 3.8 8.7 17.5 70.0
PH#2-3 369 315 5.4 6.5 14.7 73.4
positively related to the serum lipid concentration, and
approaches 0.5 as the cholesterol concentration ap-
proaches 350 mg/dL or as the sum of cholesterol and
triglyceride concentrations approaches 700 mg/dL. It is
difficult to separate the effect of cholesterol from tri-
glyceride concentrations, as these are dependent in our
sample series (r = 0.92).
Four ofthe "4C-DEHP spiked specimens analyzed by
ultracentrifugation were also analyzed by agarose gel
electrophoresis. The cholesterol concentration of these
samples ranged from 176 mg/dL to 295 mg/dL, which
is a narrower range than the series used for ultracen-
trifugation, and the correlation between lipid concen-
tration and percent of DEHP bound to the lipoprotein
fractions is not apparent from the electrophoresis data.
It should be noted, however, that this correlation was
also not apparent from the ultracentrifugation data on
the same specimens, i.e., those specimens with choles-
terol concentrations ofless than250mg/dL (Fig. 1). The
relatively weak dependence of percent DEHP binding
to lipoprotein on lipid content when the sample choles-
terol concentration is less than 250 mg/dL, with amuch
greater slope above 250 mg/dL (Fig. 1), is suggestive
of at least two lipoprotein sites ofDEHP affinity. Cho-
lesterolinthelow-density lipoprotein molecule hasbeen
shown by 13C-NMR to be in two forms (24). The major
portion is on the surface of the particle, with lesser
amounts in the core. There is an interfacial flux of the
surface cholesterol ofboth HDL and redblood cells (25);
also, thehighlylipophilic DEHPmaybe solubilized with
cholesterolesterandtriglycerideinthelipoproteincore.
By contrast, the fraction ofMEHP bound to lipopro-
tein was approximately 0.25, most of which was asso-
ciated with HDL, and was independent of the sample
lipid concentration. The remaining three-fourths was
bound to other serum proteins. That MEHP is less
strongly associated with lipoprotein than DEHP is not
surprising, in light ofthe diminished lipid solubility due
to its free carboxyl group and greater polarity. Also,
the free carboxyl group makes likely a binding to al-
bumin analogous to that of fatty acids.
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